Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 29, 2024

Dr. Reddy’s Laboratories introduces Toripalimab in India for nasopharyngeal carcinoma

Dr. Reddy's Laboratories has launched Toripalimab, the only immuno-oncology drug approved by global regulatory authorities for the treatment of nasopharyngeal carcinoma (NPC), in India.

The immuno-oncology drug is approved by global regulatory authorities for the treatment of nasopharyngeal carcinoma. Credit: National Cancer Institute on Unsplash.